Thor Medical ASA 2024 AR2
The report highlights Thor Medical's progress in 2024 as it prepares to become a leading supplier of alpha emitters for cancer therapy. Key achievements include completing and commissioning the Herøya pilot facilities on time and budget, receiving DSA authorization, and shipping the first product samples to customers. The company also secured strategic supply agreements with ARTBIO and AdvanCell, and raised NOK 173 million in a private placement to fund its first commercial-scale plant, AlphaOne. Additionally, Thor Medical received a NOK 6 million grant from Innovation Norway and approved the Final Investment Decision for AlphaOne in March 2025.
Company: Thor Medical ASA
Sector: Health Care
Country: Norway
Year: 2024
Type: AR2
Pages: 95
Thor Medical ASA
Annual Report
The report highlights Thor Medical's progress in 2024 as it prepares to become a leading supplier of alpha emitters for cancer therapy. Key achievements include completing and commissioning the Herøya pilot facilities on time and budget, receiving DSA authorization, and shipping the first product samples to customers. The company also secured strategic supply agreements with ARTBIO and AdvanCell, and raised NOK 173 million in a private placement to fund its first commercial-scale plant, AlphaOne. Additionally, Thor Medical received a NOK 6 million grant from Innovation Norway and approved the Final Investment Decision for AlphaOne in March 2025.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Workplace Fatalities
Employees